{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:50:19Z","timestamp":1793083819660,"version":"4.5.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2020YFS0326"],"award-info":[{"award-number":["2020YFS0326"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118223","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:19:44Z","timestamp":1759421984000},"page":"118223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["QS-21: Structural insights, immunological mechanisms, and prospects for rational design of safer vaccine adjuvants"],"prefix":"10.1016","volume":"301","author":[{"given":"Yanmei","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haicui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiji","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-1827","authenticated-orcid":false,"given":"Li","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118223_bib1","article-title":"QS-21: a potent vaccine adjuvant","volume":"4","author":"Zhu","year":"2016","journal-title":"Nat. Prod. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118223_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109006","article-title":"Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture","volume":"27","author":"Lv","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2025.118223_bib3","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/occmed\/kqm110","article-title":"Active and passive immunity, vaccine types, excipients and licensing","volume":"57","author":"Baxter","year":"2007","journal-title":"Occup. Med."},{"key":"10.1016\/j.ejmech.2025.118223_bib4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/exd.12925","article-title":"An inquiry into the causes and effects of the variolae (or cow\u2010pox. 1798)","volume":"25","author":"Jenson","year":"2016","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ejmech.2025.118223_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.addr.2014.10.002","article-title":"Live attenuated and inactivated viral vaccine formulation and nasal delivery: potential and challenges","volume":"93","author":"Tlaxca","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2025.118223_bib6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1359-6446(03)02864-2","article-title":"Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity","volume":"8","author":"Marciani","year":"2003","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118223_bib7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/cmdc.201200487","article-title":"Modern subunit vaccines: development, components, and research opportunities","volume":"8","author":"Moyle","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118223_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-3024.2009.01143.x","article-title":"The development of the RTS,S malaria vaccine candidate: challenges and lessons","volume":"31","author":"Ballou","year":"2009","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.ejmech.2025.118223_bib9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature10124","article-title":"A 2020 vision for vaccines against HIV, tuberculosis and malaria","volume":"473","author":"Rappuoli","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118223_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-065X.2010.00979.x","article-title":"Therapeutic cancer vaccines: are we there yet?","volume":"239","author":"Klebanoff","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejmech.2025.118223_bib11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1471-4159.2011.07458.x","article-title":"'Clinical trials in Alzheimer's disease': immunotherapy approaches","volume":"120","author":"Delrieu","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2025.118223_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/imr.12889","article-title":"Modulation of immune responses using adjuvants to facilitate therapeutic vaccination","volume":"296","author":"Schijns","year":"2020","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejmech.2025.118223_bib13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/vaccines9030222","article-title":"Natural and synthetic saponins as vaccine adjuvants","volume":"9","author":"Wang","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.ejmech.2025.118223_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1071059","article-title":"The danger model: a renewed sense of self","volume":"296","author":"M","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118223_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.imlet.2009.10.005","article-title":"The ABC of clinical and experimental adjuvants\u2014a brief overview","volume":"128","author":"Brunner","year":"2010","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ejmech.2025.118223_bib16","doi-asserted-by":"crossref","first-page":"C25","DOI":"10.1016\/j.vaccine.2010.07.021","article-title":"Unmet needs in modern vaccinology: adjuvants to improve the immune response","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib17","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118223_bib18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","article-title":"Mechanisms of action of adjuvants","volume":"4","author":"Awate","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118223_bib19","first-page":"205","article-title":"Research on saponin, an adjuvant and immunity-stimulating substance","volume":"29","author":"Richou","year":"1965","journal-title":"Ii, Rev. Immunol. Ther. Antimicrob."},{"key":"10.1016\/j.ejmech.2025.118223_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121385","article-title":"A solid-in-oil-in-water emulsion: an adjuvant-based immune-carrier enhances vaccine effect","volume":"282","author":"Tahara","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejmech.2025.118223_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: a review on adjuvants in licensed vaccines","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ejmech.2025.118223_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF02291455","article-title":"Effect of Quil A, a saponin derivative, on the response of sheep to alum precipitatedBacteroides nodosus vaccines","volume":"2","author":"Egerton","year":"1978","journal-title":"Vet. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.118223_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/308457a0","article-title":"ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses","volume":"308","author":"Morein","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118223_bib24","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/0264-410X(95)00077-E","article-title":"Structure\/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function","volume":"13","author":"Soltysik","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib25","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/S0264-410X(02)00115-9","article-title":"Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine spf66 combined with the immunological adjuvant QS-21","volume":"20","author":"Kashala","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib26","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0264-410X(00)00195-X","article-title":"Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1\u2013KLH and GD3\u2013KLH conjugates","volume":"19","author":"Kim","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib27","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1586\/erv.11.18","article-title":"Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer","volume":"10","author":"Ragupathi","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejmech.2025.118223_bib28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.146.2.431","article-title":"Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex","volume":"146","author":"Kensil","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.118223_bib29","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.vaccine.2009.01.091","article-title":"Advances in saponin-based adjuvants","volume":"27","author":"Hong-Xiang","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0020-7519(03)00053-5","article-title":"Recent advances in veterinary vaccine adjuvants","volume":"33","author":"Singh","year":"2003","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.ejmech.2025.118223_bib31","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/S0264-410X(02)00209-8","article-title":"QS-21 structure\/function studies: effect of acylation on adjuvant activity","volume":"20","author":"Liu","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1389-0344(01)00101-0","article-title":"Recent developments in adjuvants for vaccines against infectious diseases","volume":"18","author":"O'Hagan","year":"2001","journal-title":"Biomol. Eng."},{"key":"10.1016\/j.ejmech.2025.118223_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3344\/kjp.2020.33.3.201","article-title":"Recombinant zoster vaccine (Shingrix\u00ae): a new option for the prevention of herpes zoster and postherpetic neuralgia","volume":"33","author":"Singh","year":"2020","journal-title":"The Korean Journal of Pain"},{"key":"10.1016\/j.ejmech.2025.118223_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejmech.2025.118223_bib35","series-title":"Immunopotentiators in Modern Vaccines","first-page":"265","article-title":"Chapter 14 - the development of the adjuvant system AS01: a combination of two immunostimulants MPL and QS-21 in liposomes","author":"Didierlaurent","year":"2017"},{"key":"10.1016\/j.ejmech.2025.118223_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/vim.2023.0093","article-title":"Arexvy: a comprehensive review of the respiratory syncytial virus vaccine for revolutionary protection","volume":"37","author":"Swathi","year":"2024","journal-title":"Viral Immunol."},{"key":"10.1016\/j.ejmech.2025.118223_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0008-6215(95)00278-2","article-title":"Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy","volume":"280","author":"Jacobsen","year":"1996","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejmech.2025.118223_bib38","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1021\/js9504651","article-title":"Structure\u2014Function relationship among Quillaja saponins serving as excipients for nasal and ocular delivery of insulin","volume":"85","author":"Pillion","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2025.118223_bib39","series-title":"Saponins Used in Traditional and Modern Medicine","first-page":"165","article-title":"Structure\/function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria","author":"Kensil","year":"1996"},{"key":"10.1016\/j.ejmech.2025.118223_bib40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0008-6215(99)00134-2","article-title":"Separation and structural analysis of saponins in a bark extract from Quillaja saponaria Molina","volume":"320","author":"Nord","year":"1999","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejmech.2025.118223_bib41","first-page":"41","article-title":"QS-21 and QS-7: purified saponin adjuvants","volume":"92","author":"Kensil","year":"1998","journal-title":"Dev. Biol. Stand."},{"key":"10.1016\/j.ejmech.2025.118223_bib42","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1517\/13543784.7.9.1475","article-title":"QS-21: a water-soluble triterpene glycoside adjuvant","volume":"7","author":"Kensil","year":"2005","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2025.118223_bib43","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.tips.2018.03.005","article-title":"Elucidating the mechanisms of action of saponin-derived adjuvants","volume":"39","author":"Marciani","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.118223_bib44","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1021\/js9503136","article-title":"Isomerization and formulation stability of the vaccine adjuvant QS-21","volume":"85","author":"Cleland","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2025.118223_bib45","first-page":"1","article-title":"Saponins as vaccine adjuvants","volume":"13","author":"Kensil","year":"1996","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ejmech.2025.118223_bib46","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1021\/ja801008m","article-title":"Synthesis and structure verification of the vaccine adjuvant QS-7-Api. Synthetic access to homogeneous Quillaja saponaria immunostimulants","volume":"130","author":"Deng","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118223_bib47","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s00044-024-03227-x","article-title":"Development of semisynthetic saponin immunostimulants","volume":"33","author":"Bai","year":"2024","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118223_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2020.461705","article-title":"A two-step orthogonal chromatographic process for purifying the molecular adjuvant QS-21 with high purity and yield","volume":"1635","author":"Qi","year":"2021","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ejmech.2025.118223_bib49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00226-002-0150-8","article-title":"Variation of saponin contents in Quillaja saponica Molina","volume":"37","author":"Copaja","year":"2003","journal-title":"Wood Sci. Technol."},{"key":"10.1016\/j.ejmech.2025.118223_bib50","first-page":"2859","article-title":"Metabolomic analysis of saponins in crude extracts of Quillaja saponaria by liquid chromatography\/mass spectrometry for product authentication, Rapid Commun","volume":"18","author":"Kite","year":"2004","journal-title":"Mass Spectrom."},{"key":"10.1016\/j.ejmech.2025.118223_bib51","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF02866642","article-title":"Industrial uses and sustainable supply of Quillaja saponaria (rosaceae) saponins","volume":"53","author":"Mart\u00edn","year":"1999","journal-title":"Econ. Bot."},{"key":"10.1016\/j.ejmech.2025.118223_bib52","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/S0264-410X(99)00560-5","article-title":"Preparation and characterisation of quillaja saponin with less heterogeneity than Quil-A","volume":"18","author":"Kamstrup","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib53","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/1097-0010(200011)80:14<2063::AID-JSFA750>3.0.CO;2-2","article-title":"Quality control of commercial quillay (Quillaja saponaria Molina) extracts by reverse phase HPLC","volume":"80","author":"Mart\u00edn","year":"2000","journal-title":"J. Sci. Food Agric."},{"key":"10.1016\/j.ejmech.2025.118223_bib54","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1021\/ja062364i","article-title":"Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Api","volume":"128","author":"Kim","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118223_bib55","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1021\/ja0422007","article-title":"Synthesis of the potent immunostimulatory adjuvant QS-21A","volume":"127","author":"Wang","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118223_bib56","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1002\/anie.200801885","article-title":"Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine","volume":"47","author":"Deng","year":"2008","journal-title":"Angew. Chem.-Int. Edit."},{"key":"10.1016\/j.ejmech.2025.118223_bib57","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1016\/j.vaccine.2010.04.034","article-title":"Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins","volume":"28","author":"Ragupathi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib58","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1021\/ja9082842","article-title":"Design and synthesis of potent Quillaja saponin vaccine adjuvants","volume":"132","author":"Adams","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118223_bib59","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1021\/acs.accounts.6b00242","article-title":"Development of improved vaccine adjuvants based on the saponin natural product QS-21 through chemical synthesis","volume":"49","author":"Fern\u00e1ndez-Tejada","year":"2016","journal-title":"Accounts Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118223_bib60","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3390\/vaccines12121435","article-title":"Plant cell culture-derived saponin adjuvant enhances immune response against a stabilized human metapneumovirus pre-fusion vaccine candidate","volume":"12","author":"Swart","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.ejmech.2025.118223_bib61","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41589-023-01538-5","article-title":"Complete biosynthesis of the potent vaccine adjuvant QS-21","volume":"20","author":"Martin","year":"2024","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118223_bib62","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.vaccine.2009.12.084","article-title":"Vaccine adjuvants: a priority for vaccine research","volume":"28","author":"Harandi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib63","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-4899-1367-8_15","article-title":"Structure\/function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria","volume":"404","author":"Kensil","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2025.118223_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.152905","article-title":"Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review","volume":"60","author":"Lacaille-Dubois","year":"2019","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2025.118223_bib65","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1002\/chem.202004705","article-title":"Replacing the rhamnose-xylose moiety of QS-21 with simpler terminal disaccharide units attenuates adjuvant activity in truncated saponin variants","volume":"27","author":"Fuentes","year":"2021","journal-title":"Chemistry"},{"key":"10.1016\/j.ejmech.2025.118223_bib66","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nchem.1963","article-title":"Development of a minimal saponin vaccine adjuvant based on QS-21","volume":"6","author":"Fern\u00e1ndez-Tejada","year":"2014","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejmech.2025.118223_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.865507","article-title":"Novel oxime-derivatized synthetic triterpene glycosides as potent saponin vaccine adjuvants","volume":"13","author":"Fuentes","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118223_bib68","doi-asserted-by":"crossref","first-page":"9560","DOI":"10.1021\/acs.joc.6b00922","article-title":"Synthesis and evaluation of QS-21-based immunoadjuvants with a terminal-functionalized side chain incorporated in the west wing trisaccharide","volume":"81","author":"Wang","year":"2016","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.118223_bib69","doi-asserted-by":"crossref","first-page":"14589","DOI":"10.1021\/acs.jmedchem.2c01087","article-title":"Structure-activity relationship study of momordica saponin ii derivatives as vaccine adjuvants","volume":"65","author":"Kim","year":"2022","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118223_bib70","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1021\/acs.jmedchem.4c02173","article-title":"Chain length does matter: development of high-potency QS-21-based vaccine adjuvants","volume":"68","author":"Luo","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118223_bib71","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3389\/fimmu.2016.00663","article-title":"Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21","volume":"7","author":"Welsby","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118223_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13324","article-title":"Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation","volume":"7","author":"den Brok","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118223_bib73","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/pathogens9040252","article-title":"Inflammasomes as targets for adjuvants","volume":"9","author":"Ivanov","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.ejmech.2025.118223_bib74","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1074\/jbc.M115.683011","article-title":"Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants","volume":"291","author":"Marty-Roix","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118223_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/srep39475","article-title":"Central role of CD169+ lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01","volume":"6","author":"Detienne","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118223_bib76","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.4049\/jimmunol.148.8.2357","article-title":"Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses","volume":"148","author":"Newman","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.118223_bib77","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/978-1-4615-1823-5_22","article-title":"Structural and immunological characterization of the vaccine adjuvant QS-21","volume":"6","author":"Kensil","year":"1995","journal-title":"Pharmaceut. Biotechnol."},{"key":"10.1016\/j.ejmech.2025.118223_bib78","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0264-410X(94)80052-2","article-title":"Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma","volume":"12","author":"Livingston","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib79","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/cancers11050677","article-title":"MAGE-A3 is a clinically relevant target in undifferentiated Pleomorphic Sarcoma\/Myxofibrosarcoma","volume":"11","author":"Conley","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118223_bib80","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein e vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib81","year":"2021"},{"key":"10.1016\/j.ejmech.2025.118223_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17460441.2019.1667329","article-title":"How plausible is an Alzheimer's disease vaccine?","volume":"15","author":"Cacabelos","year":"2020","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118223_bib83","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1016\/j.vaccine.2005.06.016","article-title":"Haemolytic activities and adjuvant effect of Astragalus membranaceus saponins (AMS) on the immune responses to ovalbumin in mice","volume":"23","author":"Yang","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib84","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"Glaxosmithkline adjuvant systems in vaccines: concepts, achievements and perspectives","volume":"6","author":"Gar\u00e7on","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejmech.2025.118223_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1102524","article-title":"Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21","volume":"14","author":"Alving","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118223_bib86","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/21645515.2016.1225635","article-title":"From discovery to licensure, the adjuvant system story","volume":"13","author":"Gar\u00e7on","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.ejmech.2025.118223_bib87","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1016\/j.vaccine.2022.08.048","article-title":"First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-na\u00efve adults","volume":"40","author":"Hutter","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib88","year":"2020","journal-title":"Phase 1 clinical trial with controlled human malaria infection (CHMI) for safety, protective efficacy, and immunogenicity of plasmodium falciparum malaria protein (FMP014) administered intramuscularly with ALFQ healthy malaria-na\u00efve adults"},{"key":"10.1016\/j.ejmech.2025.118223_bib89","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1271\/bbb.110182","article-title":"Stimulating macrophage activity in mice and humans by oral administration of Quillaja saponin","volume":"75","author":"Naknukool","year":"2011","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.ejmech.2025.118223_bib90","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1073\/pnas.051626298","article-title":"Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial","volume":"98","author":"Gilewski","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2025.118223_bib91","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1158\/1078-0432.CCR-03-0101","article-title":"Vaccination of small cell lung cancer patients with polysialic acid or n-propionylated polysialic acid conjugated to keyhole limpet hemocyanin","volume":"10","author":"Krug","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118223_bib92","first-page":"e34","article-title":"Safety and allele-specific immunogenicity of a malaria vaccine in malian adults: results of a phase I randomized trial, PLoS Clin","volume":"1","author":"Thera","year":"2006","journal-title":"Trials"},{"key":"10.1016\/j.ejmech.2025.118223_bib93","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1016\/j.vaccine.2007.01.073","article-title":"Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant","volume":"25","author":"Mbawuike","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib94","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1016\/S2666-5247(23)00410-X","article-title":"SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial","volume":"5","author":"Ober Shepherd","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ejmech.2025.118223_bib95","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1016\/j.vaccine.2021.05.028","article-title":"Safety and immunogenicity of different clostridioides (clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50\u201385 years","volume":"39","author":"Lawrence","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib96","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00262-020-02503-0","article-title":"The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients","volume":"69","author":"Rosenbaum","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejmech.2025.118223_bib97","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/S0264-410X(00)00415-1","article-title":"QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans","volume":"19","author":"Evans","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib98","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1016\/j.vaccine.2005.01.072","article-title":"A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 or QS-21","volume":"23","author":"Slovin","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib99","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.vaccine.2004.11.034","article-title":"Potent enhancement of cellular and humoral immune responses against recombinant hepatitis b antigens using AS02A adjuvant in healthy adults","volume":"23","author":"Vandepapeli\u00e8re","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00262-011-1083-6","article-title":"Immunization with N-propionyl polysialic acid\u2013KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci","volume":"61","author":"Krug","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejmech.2025.118223_bib101","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/cancers8040046","article-title":"A phase I study of unimolecular pentavalent (Globo-H-GM2-sTn-TF-Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission","volume":"8","author":"O'Cearbhaill","year":"2016","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118223_bib102","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early ifn\u03b3 response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"npj vaccines"},{"key":"10.1016\/j.ejmech.2025.118223_bib103","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.vaccine.2007.12.038","article-title":"Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers","volume":"26","author":"Vandepapeli\u00e8re","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/srep29368","article-title":"Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the nanopatch, resulted in adjuvant dose sparing","volume":"6","author":"Ng","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118223_bib105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.phymed.2017.10.019","article-title":"New perspectives for natural triterpene glycosides as potential adjuvants","volume":"37","author":"Lacaille-Dubois","year":"2017","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2025.118223_bib106","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.vaccine.2009.01.091","article-title":"Advances in saponin-based adjuvants","volume":"27","author":"Sun","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2025.118223_bib107","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41586-024-07345-9","article-title":"Complete biosynthesis of QS-21 in engineered yeast","volume":"629","author":"Liu","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118223_bib108","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10337-018-3494-4","article-title":"Orthogonal separations in reversed-phase chromatography","volume":"81","author":"Agrawal","year":"2018","journal-title":"Chromatographia"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:06:04Z","timestamp":1773147964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":108,"alternative-id":["S0223523425009882"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118223","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"QS-21: Structural insights, immunological mechanisms, and prospects for rational design of safer vaccine adjuvants","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118223"}}